High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Yan LiFanshuang ZhangPei YuanLei GuoJian-Ming YingJie HePublished in: Thoracic cancer (2020)
High concordance of ctDNA and tissue biopsy was observed. NGS of ctDNA from 147 TKI-relapsed patients showed that both high ratio of T790M sensitizing mutation (sensi-mutation) and high MAFs of mutations were all associated with better third generation TKI treatment outcomes. The quantification of both MAFs and T790M sensi-mutation ratio should be taken into consideration in some clinical situations, and incorporation of high-throughput NGS into clinical trials may be crucial to identifying the response to osimertinib, as it provides more comprehensive genomic information.
Keyphrases
- tyrosine kinase
- high throughput
- clinical trial
- small cell lung cancer
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- chronic kidney disease
- acute lymphoblastic leukemia
- healthcare
- newly diagnosed
- metabolic syndrome
- prognostic factors
- gene expression
- circulating tumor
- dna methylation
- chronic myeloid leukemia
- health information
- weight loss